PharmTech

FDA Approves Teclistamab Plus Daratumumab for Relapsed/Refractory Multiple Myeloma

FDA granted full approval to teclistamab plus daratumumab/hyaluronidase for RRMM after ≥1 prior line, marking first bispecific T-cell engager conversion from ...